Efficacy and Prognosis of HA380 Perfusion Combined with Continuous Venovenous Hemofiltration in the Treatment of Sepsis

Abstract

Background: Effect of HA380 perfusion combined with continuous venovenous hemofiltration (CVVH) on sepsis and prognosis. Methods: 60 patients with sepsis admitted to our hospital from November 2020 to March 2022 were selected as the research objects and divided into two groups by simple random method. The two groups were given medical treatment according to the sepsis diagnosis and treatment guidelines jointly issued by the American Society of Critical Care Medicine and the European Society of Critical Care Medicine. The control group was treated with CVVH, and the observation group was treated with HA380 perfusion combined with CVVH. Results: Intestinal fatty acid binding protein, diamine oxidase, D-lactic acid, interleukin-6, tumor necrosis factor-α, endotoxin, C-reaction protein, white blood cell, procalcitonin, blood lactic acid, serum creatinine, blood urea nitrogen, bilirubin, intra-abdominal pressure, one-day body temperature peak, sequential organ function score at 24 h, 48 h, and 72 h after treatment were lower than those at baseline, mean arterial pressure and oxygenation index were higher than those at baseline, with statistical significance (p < 0.05). Conclusion: HA380 perfusion combined with CVVH in the treatment of sepsis can reduce intestinal barrier function damage and inflammation, and improve short-term prognosis. Clinical Trial Registration: Chinese clinical trial registry. Number: ChiCTR2400082281.